1. Home
  2. AAUC vs EWTX Comparison

AAUC vs EWTX Comparison

Compare AAUC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AAUC

Allied Gold Corporation

HOLD

Current Price

$31.11

Market Cap

3.9B

Sector

N/A

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$31.76

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAUC
EWTX
Founded
N/A
2017
Country
Canada
United States
Employees
2252
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.3B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AAUC
EWTX
Price
$31.11
$31.76
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$37.38
AVG Volume (30 Days)
262.0K
721.7K
Earning Date
03-31-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$82.23
N/A
Revenue Next Year
$55.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.40
$10.60
52 Week High
$32.08
$31.82

Technical Indicators

Market Signals
Indicator
AAUC
EWTX
Relative Strength Index (RSI) 51.66 60.66
Support Level $30.99 $26.91
Resistance Level $31.73 N/A
Average True Range (ATR) 0.33 1.50
MACD -0.13 0.11
Stochastic Oscillator 57.69 82.26

Price Performance

Historical Comparison
AAUC
EWTX

About AAUC Allied Gold Corporation

Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, the development of new mines, the advancement of its exploration properties, and, targeting other consolidation opportunities with a focus on Africa.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: